Global Chronic Kidney Disease (Ckd) Drugs Market Set To Grow To $15.6bn By 2022

06 August 2018
Pharma

Visiongain has launched a new pharma report Global Chronic Kidney Disease (CKD) Drugs Market Report : ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Chronic kidney disease (CKD) is a major risk multiplier factor for cardiovascular disease, diabetes, hypertension, inflammatory disease of kidney (glomerulonephritis), and aging. CKD may lead to kidney injury and sometimes to complete loss of kidney function, thus leading to renal replacement therapy. According to World Kidney Day, a global awareness campaign, an estimated of 10% of worldwide population is affected by CKD. According to the Centers for Disease Control and Prevention (CDC), more than 26 million Americans are affected by CKD. CKD leads to end stage renal disease (ESRD) if untreated. It was estimated by the National Kidney Foundation in 2015 that about 468,000 ESRD patients are on dialysis in the U.S. alone.

The lead analyst of the report commented “The chronic kidney disease drugs market is set to experience considerable growth over the next decade. The main growth drivers of this market are increasing prevalence of chronic kidney disease (CKD) worldwide, promising pipeline, approval of novel molecules, and increasing incidence of cardiovascular disorders and diabetes. One of the major restraints of the chronic kidney disease drugs market is patent expirations of some of the major brands which are likely to result in introduction of substitutes and cheaper biosimilars.”

Leading companies featured in the report include Pfizer, Amgen, Roche, Abbott, GlaxoSmithKline (GSK), Sanofi, Morepen Laboratories, Baxter, Allergan, Japan Chemical Research Pharmaceuticals Co., Ltd.)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever